FWD 2 Commission E: Haronga bark and leaf

  The Commission E Monographs

Haronga bark and leaf


Harunganae madagascariensis cortex et folium
Harongarinde und bltter
Published March 13, 1990

Name of Drug

Harunganae madagascariensis cortex et folium, haronga bark and leaf.  

Composition of Drug

Haronga bark with dried leaves consists of the bark and leaves of Harungana madagascariensis Lamarck ex Poiret [Fam.  Hypericaceae], as well as its preparations in effective dosage.  

The bark contains 1,8-dihydroxyanthracene derivatives, such as harunganin and madagascin.  

The leaf contains dimers of 1,8-dihydroxyanthracene derivatives, such as hypericin and pseudohypericin.  

Uses

Dyspepsia, mild exocrine pancreatic insufficiency.  

Contraindications

Acute pancreatitis and acute attacks of chronic recurring pancreatitis, severe liver function disorders, gallstones, obstruction of bile ducts, gall bladder empyema, ileus.  

Side Effects

None known.  

Warning:Photosensitivity is especially possible in fair-skinned individuals.  

Interactions with Other Drugs

None known.  

Dosage

Unless otherwise prescribed:

Average daily dosage:

  • 7.5 - 15 mg of an aqueous-alcoholic dry extract corresponding to 25 - 50 mg drug;
  • equivalent preparations.  

Mode of Administration

Preparations of haronga bark with leaves for oral use.  

Duration of Administration

Preparations of haronga bark with leaves must not be taken longer than 2 months.  

Action

Stimulation of the excretory function of the pancreas
Stimulation of the gastric juice secretion
Choleretic
Cholecystokinetic